Market closedNon-fractional
Summit Therapeutics/SMMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
SMMT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Miami, United States
Employees
105
Website
www.summittxinc.com
SMMT Metrics
BasicAdvanced
$7.4B
Market cap
-
P/E ratio
-$0.17
EPS
-1.13
Beta
-
Dividend rate
Price and volume
Market cap
$7.4B
Beta
-1.13
Financial strength
Current ratio
6.966
Quick ratio
6.725
Long term debt to equity
239.364
Total debt to equity
247.731
Interest coverage (TTM)
-5.87%
Management effectiveness
Return on assets (TTM)
-33.27%
Return on equity (TTM)
-130.59%
Valuation
Price to book
166.56
Price to tangible book (TTM)
173.94
Price to free cash flow (TTM)
-12.919
Growth
Earnings per share change (TTM)
-92.73%
3-year earnings per share growth (CAGR)
-42.56%
What the Analysts think about SMMT
Analyst Ratings
Majority rating from 3 analysts.
SMMT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$43M
18.90%
Profit margin
0.00%
NaN%
SMMT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$0.06
-
Expected
-$0.06
-$0.06
Surprise
0.00%
-
SMMT News
AllArticlesVideos
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
Business Wire·2 months ago
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Business Wire·2 months ago
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Summit Therapeutics stock?
Summit Therapeutics (SMMT) has a market cap of $7.4B as of July 27, 2024.
What is the P/E ratio for Summit Therapeutics stock?
The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of July 27, 2024.
Does Summit Therapeutics stock pay dividends?
No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Summit Therapeutics dividend payment date?
Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Summit Therapeutics?
Summit Therapeutics (SMMT) has a beta rating of -1.13. This means that it has an inverse relation to market volatility.
Buy or sell Summit Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.